Navican Raises $15 Million Series A Financing to Commercialize TheraMap and Expand Precision Cancer Care Offering

Financing led by Intermountain Healthcare

SALT LAKE CITY, UTAH, USA, June 2, 2017 / -- Navican Genomics, Inc., a Precision Cancer Care company that offers a comprehensive cancer services for oncologists and patients, announced that the company has closed $15 million Series A financing led by Intermountain Healthcare. Navican will use the financing to accelerate commercialization and expansion of the company’s Precision Cancer Care offering, including their TheraMap solution, which harnesses the power of precision genomics, clinical analytics, and patient services for optimal cancer management.

Navican, an Intermountain Healthcare company, provides testing and treatment options for the greatest number of actionable gene mutations, and offers the most advanced next-generation sequencing available. Currently, only a small percentage of people who have cancer are benefiting from the promise of precision medicine and targeted therapies. With Series A funding, Navican will commercialize TheraMap to make precision medicine available to everyone with cancer.

According to Ingo Chakravarty, chief executive officer and president of Navican, current precision medicine solutions fall short of delivering the best care individualized to each person. “While precision medicine has great potential to positively impact cancer patients, its use is currently fragmented, at best. TheraMap will provide community based patients with access to the best possible care, which means precision care for all cancer patients, not just a few,” said Chakravarty. “We are privileged to be supported by, and partner with, Intermountain Healthcare as we commercialize TheraMap and to expand our Precision Cancer Care offering.”

Intermountain Healthcare is a not-for-profit organization that takes an expansive, innovative, and holistic approach to understanding what people want and need to live the healthiest lives possible. This lofty aspiration requires Intermountain to anticipate and understand the evolving market place, and be at the forefront of innovations that improve health and care. Intermountain created the Intermountain Innovations division in 2013 to advance industry collaboration and commercialize intellectual property that has demonstrably proven to improve healthcare and satisfy expectations of managing costs.

“Innovation is a top priority at Intermountain Healthcare,” says Marc Harrison, MD, chief executive officer and president of Intermountain Healthcare. “As we develop incredible advancements that will improve healthcare outcomes, we are excited to partner with companies such as Navican to serve patients and communities around the world.”

For more information on Navican or to request of a demo of TheraMap, visit

About Navican

NAVICAN, an Intermountain Healthcare company, offers Precision Cancer Care to transform and advance cancer care for patients everywhere that advanced therapies are available. Navican offers expert therapy recommendations and experienced navigators to help patients and their caregivers get the precision therapy they need as soon as possible. Navican helps oncologists and patients harness the power of precision medicine to improve outcomes and reduce cost. For more information, please visit us at

About Intermountain Healthcare

Intermountain Healthcare is a Utah-based not-for-profit system of 22 hospitals, 180 clinics, a Medical Group with about 1,500 employed physicians and advanced practitioners, a health plans group called SelectHealth, and other medical services. Intermountain is widely recognized as a leader in transforming healthcare through high quality and sustainable costs. For more information, visit

Daron Cowley
Intermountain Healthcare
email us here

Thank you for visiting Navican

To view the site, please update your browser

The Navican site works on all modern browsers with legacy support back through Internet Explorer 9. Please update by going to the link below.

Update Browser